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Thrombus aspirationAbstract Objective: To compare the procedural and clinical outcomes in patients with STEMI
treated with PCI and manual thrombus aspiration versus PCI alone regarding mortality at 30 days
(primary endpoint), TIMI flow grade, target vessel revascularization, heart failure, length of hospi-
tal stay and complications of PCI during index hospitalization (secondary endpoints). A prospective
study done in the Faculty of Medicine, Alexandria Main University Hospital and ICC Hospital.
Subjects: 160 patients in the setting of primary PCI in the duration from January 2014 to January
2015. Patients were divided into two groups: Group 1: 80 patients with thrombus aspiration; Group
2: 80 patients with no thrombus aspiration.
Methods: All patients were treated with primary PCI and evaluated by echocardiography with
assessment of ejection fraction. Observation to detect the occurrence of any in-hospital MACE
or other PCI complications. Follow-up at 30 days for death or rehospitalization.
Results: The peak of post procedural CK-MB (151.8 U/L vs. 131.2 U/L, P= 0.026) was signifi-
cantly lower in group 2. There was no statistically significant difference between both groups as
regards pre-discharge ejection fraction (45.63 ± 10.86% vs. 42.37 ± 10.14) P= 0.171. Also there
were no statistically significant differences between both groups as regards TIMI flow
(P= 0.403), or incidence of no reflow (P= 0.615). Stroke perforation and cardiac tamponade
did not occur in both groups. Heart failure occurred in 10 patients (12.5%) in group 1, and in
12 patients (15%) in group 2 with no statistical significance. Stent thrombosis did not occur in
any patient in the two groups. Rehospitalization due to cardiac cause was less in group 1 [2 patients
(2.5%)] than in group 2 [6 patients (7.5%)] with no statistical significance P= 0.615. Mortality
after 30 days was the same in both groups, and 4 patients (5%) died in each group P= 1.
Conclusion: Thrombus aspiration had no additional benefit over conventional PCI regarding
mortality, left ventricular function, length of hospital stay, rehospitalization due to cardiac cause
and complications of PCI. Routine thrombus aspiration is not recommended especially in patients
with low thrombus grade.
 2016 The Author. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
148 S.W. Ayad1. Introduction
ST-elevation myocardial infarction (STEMI) remains one of
the leading causes of death globally.1 Primary percutaneous
coronary intervention (PCI) was established as a golden ther-
apeutic standard.2 One of the most important remaining ther-
apeutic challenges in STEMI is establishment of normal
coronary flow after PCI because reduced flow is associated
with death and heart failure.3,4
While this treatment alleviates the major acute problem of
having an occluded or highly stenosed coronary artery, distal
embolization of thrombus material often precludes restoration
of normal coronary artery flow and thrombus material is also
thought to play an important role in reperfusion injury.5
Thrombus aspiration is easy, quickly performed and a
cheap adjunct to primary PCI and may contribute to improve
coronary artery flow post PCI.6–10 However, most previous
studies on thrombus aspiration have not been powered for
hard clinical endpoints, such as mortality.
Thrombus aspiration has been proposed as an adjunctive
therapy to protect microcirculation from distal embolization,
which frequently occurs in patients presenting with STEMI
treated with primary PCI.11
In spite of its appealing conceptual value, this therapy has
been downgraded from class IIa level of evidence B recommen-
dation in ESC guidelines for the management of acute myocar-
dial infarction in patients presenting with ST-segment
elevation 2012 to class IIb level of evidence A recommendation
in ESC guidelines for myocardial revascularization 2014. This
was a consequence of conflicting results yielded in randomized
clinical trials.12,13
Also in the recent AHA/SCAI recommendations for Pri-
mary PCI published in 2015, Aspiration thrombectomy has
been classified as class IIb recommendation instead of IIa in
2013 and only for selective and bailout aspiration. A new rec-
ommendation Class III was added: No Benefit added for rou-
tine aspiration thrombectomy before PCI.14
Several factors might have accounted for discrepancies
between trials such as differences in clinical presentation
among recruited patients and heterogeneity in angiographic
characteristics, e.g. inclusion of both occluded and patent cul-
prit vessels at the time of the initial coronary angiography. In
addition, the type of aspiration device used seems to be an
important determinant of procedural and clinical outcome.
Recent meta-analyses have shown consistent benefit of simple
catheter-based thrombus aspiration over complex devices aim-
ing at mechanical thrombectomy or embolic protection.15–17
Risks in using aspiration catheters include coronary spasm,
distal embolization during crossing, dissection, perforation,
and proximal displacement of thrombus with potential
embolization down previously unaffected arteries. Good tech-
nique and improved catheter design can reduce these risks to
some extent.
1.1. Aim
The study was designed to compare the procedural and clinical
outcomes in patients with STEMI treated with PCI and man-
ual thrombus aspiration versus PCI alone regarding mortality
at 30 days (primary endpoint), TIMI flow grade, target vessel
revascularization, heart failure, length of hospital stay andcomplications of PCI during index hospitalization (secondary
endpoints).
1.2. Patients
A total of 160 patients were included in the study. Individuals
for inclusion were recruited among the patients presenting to
the participating centers (International cardiac center ‘‘ICC”
and Alexandria University hospital) in the setting of primary
PCI because of STEMI in the duration from January 2014
to January 2015.
Patients enrolled in the study were assigned to two groups:
 Group 1: 80 patients with thrombus aspiration.
 Group 2: 80 patients with no thrombus aspiration.
Inclusion criteria
 Patients with a diagnosis of STEMI defined as chest
pain suggestive for myocardial ischemia for at least
30 min before hospital admission. Time from onset of
symptoms of less than 24 h, and an ECG with new
ST-segment elevation in two or more contiguous leads
of P0.2 mV in leads V2–V3 and/or P0.1 mV in other
leads or a probable new-onset left bundle branch
block.18
 Correspondence between ECG findings and culprit
artery pathoanatomy.
 A minimum of 70% stenosis in culprit artery by visual
estimate.
 Possibility to perform thrombus aspiration.
 Patients with low thrombus burden (thrombus TIMI
grades 1, 2 and 3).19
Exclusion criteria
 Need for emergency coronary artery bypass grafting.
 Prior myocardial infarction.
 Previous open chest surgery.
 Inability to perform thrombus aspiration.
 Patients with high thrombus burden or no thrombus
present (thrombus TIMI grade, 4 and 5).19
 Inability to provide informed consent.
All patients participating in the study signed required
consents.2. Methods
This was a prospective study. Treatment strategy was assigned
based on operator’s discretion.
 Medical history, clinical examination and ECG for all
participating patients.
 Cardiac biomarkers Troponin I and CK-MB on admis-
sion, with repeated CK-MB immediate after PCI and
follow-up during index hospitalization (every 24 h).
 Echocardiography after primary PCI during hospital
stay with assessment of ejection fraction using the mod-
ified Simpson method.
Table 1 Comparison between two studied groups according
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as regards the following:to demographic data and risk factors.
Group 1
(n= 80)
Group 2
(n= 80)
Test of Sig. P
No. % No. %
Age
Mean ± SD 57.98 ± 6.19 60.85 ± 8.33 t= 1.753 0.084
HTN 34 42.5 32 40.0 v2 = 0.052 0.820
DM 30 37.5 24 30.0 v2 = 0.503 0.478
Smoker 44 55 52 65 v2 = 0.833 0.361
Dyslipidemia 42 52.5 36 45.0 v2 = 0.450 0.502
v2: Chi square test.Site of the occlusion.
Severity of the occlusion.
TIMI flow grade (assessed before wire passage).
Thrombus TIMI grade.
Myocardial blush grade.
 Glycoprotein IIb/IIIa inhibitors used according to the
guidelines as bailout therapy in the event of angio-
graphic evidence of large thrombus, slow or no-reflow
(inadequate myocardial perfusion through a given seg-
ment of the coronary circulation without angiographic
evidence of mechanical vessel obstruction).20,21
 Patients were observed for outcomes.
t: Student’s t-test.
HTN: Hypertension.
Table 2 Comparison between two studied groups according
to initial clinical assessment.
Group 1
(n= 80)
Group 2
(n= 80)
Test of Sig. P
No. % No. %
Killip class
I 56 70.0 50 62.5 v2 = 0.727 MCP= 0.877
II 6 7.5 8 10.0
III 14 17.5 16 20.0
IV 4 5.0 6 7.5
Infarction location
Anterior 46 57.5 40 50.0 v2 = 0.916 0.633
Inferior 22 27.5 30 37.5
Lateral 12 15.0 10 12.5
v2: value for Chi square.
MC: Monte Carlo test.
t: Student’s t-test.
Table 3 Comparison between two studied groups according
to angiographic analysis.
Group 1 (n= 80) Group 2 (n= 80) v2 P
No. % No. %
No. of diseased vessels
1 40 50.0 50 62.5 2.873 MCP= 0.229
2 36 45.0 22 27.5
3 4 5.0 8 10.0
Infarct related artery
LAD 46 57.5 40 50.0 0.458 0.795
LCX 14 17.5 16 20.0
RCA 20 25.0 24 30.0
Thrombus TIMI grade
1 12 15.0 10 12.5 0.224 0.894
2 20 25.0 18 22.5
3 48 60.0 52 65.0
Initial TIMI flow
0 40 50 40 50 1.726 MCP= 0.293
I 33 41.25 28 35
II 7 8.75 12 15Primary outcome is mortality at 30 days.
Secondary outcomes include TIMI flow grade after PCI,
need for target vessel revascularization and heart failure
at 30 days, length of hospital stay and complications of
PCI during index hospitalization (stroke, perforation,
cardiac tamponade and bleeding).
At 30 days responsible physician followed up patients
directly or via telephone interview.
 Non-culprit lesions were scheduled as planned staged
procedures for both groups.
2.1. Statistical analysis
Data were fed to the computer and analyzed using IBM SPSS
software package version 20.0.22
Qualitative data were described using number and percent.
Quantitative data were described using Range (minimum and
maximum), mean, standard deviation and median.
Comparison between different groups regarding categorical
variables was tested using Chi-square test. When more than
20% of the cells have expected count less than five, correction
for chi-square was conducted using Fisher’s Exact test or
Monte Carlo correction.
The distribution of quantitative variables was tested for
normality using Kolmogorov–Smirnov test, Shapiro–Wilk test
and D’Agostino test. If it revealed normal data distribution,
parametric tests were applied. If data were abnormally dis-
tributed, non-parametric tests were used.
For normally distributed data, comparison between two
independent populations was done using independent t-test.
For abnormally distributed data, comparison between two
independent populations was done using Mann–Whitney U-
test.
Significance of the obtained results was judged at the 5%
level.
3. Results
Both groups matched well regarding demographic data and
risk factors (Table 1). There was no statistical difference
regarding initial clinical assessment (Killip class, type of infarc-
tion) (Table 2).
There were no statistically significant differences regarding
the number of diseased vessels, infarct related artery, lesion
type and number, thrombus TIMI grade and initial TIMI flow
(Table 3).
Table 6 Comparison between two studied groups according
to procedural results.
Group 1 (n= 80) Group 2 (n= 80) v2 P
No. % No. %
TIMI flow
I 2 2.5 4 5.0 2.082 MCP= 0.403
II 8 10.0 16 20.0
III 70 87.5 60 75.0
MBG
1 4 5.0 6 7.5 8.868 MCP= 0.024
2 6 7.5 14 17.5
3 10 12.5 26 32.5
4 60 75.0 34 42.5
No reflow
2 2.5 6 7.5 1.053 FEP= 0.615
v2: value for Chi square.
MC: Monte Carlo test.
FE: Fisher Exact test.
Table 7 Comparison between two studied groups according
to clinical end points at 30 days.
Group 1 (n= 80) Group 2 (n= 80) v2 P
No. % No. %
Rehospitalization
2 2.5 6 7.5 1.053 FEP= 0.615
Death
4 5.0 4 5.0 0.0 FEP= 1.000
FE: Fisher Exact test.
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334 min in group 2 which was not statistically significant
(Table 4).
Glycoprotein IIb/IIIa inhibitors were used in 24 (30%)
patients in group 1, and in 30 (37.5%) patients in group 2
which was not statistically significant (Table 4).
The peak of post procedural CK-MB was significantly
lower in group 2 than in group 1 (P= 0.026) (Table 5).
In addition, there was no statistically significant difference
between both groups as regards pre-discharge ejection fraction
(Table 5).
Regarding the procedure results, there were no significant
difference between the two groups in TIMI flow at the end
of PCI, (P= 0.403), while myocardial blush grade was signif-
icantly better in patients of group 1 (P= 0.024).
No reflow occurred less in group 1 than in group 2. How-
ever, it was not statistically significant (Table 6).
In this study, no failure to cross the aspiration catheter
through the lesion was found during thrombus aspiration in
group 1.
Stroke, neurologic complications, perforation, and cardiac
tamponade did not occur in any case in both groups.
Heart failure occurred in 10 (12.5%) patients in group 1,
and in 12 (15%) patients in group 2 with no statistical
significance.
The mean length of hospital stay was 4.7 (±1.33) days in
group 1, and 5.1 (±1.86) days in group 2 with no statistical
significance.
Stent thrombosis did not occur in any patient in the two
groups.
Rehospitalization due to cardiac cause was less in group 1
[2 patients (2.5%)] than in group 2 [6 patients (7.5%)]. How-
ever, that was not statistically significant. Mortality after
30 days was the same in both groups. Four (5%) patients died
in each group (Table 7).Table 4 Time from onset to PCI, use of GP IIb/IIIa
antagonist.
Group 1
(n= 80)
Group 2
(n= 80)
Test of Sig. P
No. % No. %
Time from onset to PCI
Mean ± SD 384.25 ± 157.30 334.37 ± 125.88 t= 1.566 0.121
GP IIb/IIIa antagonist
Yes 24 30.0 30 37.5 v2 = 0.503 0.478
v2: value for Chi square.
t: Student’s t-test.
Table 5 Comparison between two studied groups according
to CKMB & EF.
Group 1 (n= 80) Group 2 (n= 80) t P
Peak CKMB
Mean ± SD 151.78 ± 41.82 131.20 ± 39.09 2.273 0.026
EF
Mean ± SD 45.63 ± 10.86 42.37 ± 10.14 1.383 0.1714. Discussion
Thrombus aspiration is a simple, rapidly performed, and rela-
tively inexpensive adjunct to PCI that may improve blood flow
and via thrombus removal help in restoration of epicardial
flow, and myocardial reperfusion.23
We decided to perform a real-life prospective study to com-
pare the procedural and clinical outcomes in patients with
STEMI treated with PCI and manual thrombus aspiration ver-
sus PCI alone regarding mortality at 30 days (primary end-
point), TIMI flow grade, target vessel revascularization,
heart failure, length of hospital stay and complications of
PCI during index hospitalization (secondary endpoints).
Our study showed that the peak of post procedural CK-MB
was significantly lower in group 2 than group 1. However,
there was no significant difference between both groups as
regards pre-discharge ejection fraction. More patients in
thrombus aspiration group achieved post procedure TIMI
III flow but this was not statistically significant. The same find-
ings were reported by Svilaas et al.24 in the famous Thrombus
Aspiration during percutaneous coronary intervention in
Acute myocardial infarction Study (TAPAS) trial, which
showed no significant difference in postprocedural TIMI flow
grade 3 between thrombus aspiration and conventional PCI
groups (86% vs. 82.5%; P= 0.12).
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rates of TIMI 3 flow after PCI were the same (93.1%) in the
two groups (P= 0.12).
In our study the use of manual thrombus aspiration
resulted in significantly better reperfusion as 60 cases (75%)
of those with thrombus aspiration had MBG 4 while only 34
patients representing (42.5%) of those without thrombus aspi-
ration achieved MBG 4. The same was reported by Svilaas
et al.24 in TAPAS trial and De Carlo et al.26, who concluded
that thrombectomy group showed a significantly higher rate
of final MBG 3 (68.3% vs. 52.9%; P= 0.03). De Luca et al.16
in a meta-analysis of 9 randomized trials, concluded that
adjunctive manual thrombectomy devices were associated with
a significantly higher rate of postprocedural MBG 3 (52.1% vs.
31.7%, p< 0.001).
In our study we noticed that the peak of post procedural
CK-MB was significantly higher in the thrombectomy group
(P value = 0.026).
On the other hand Burzotta et al.9 in the REMEDIA trial
and Silva-orrego et al.27 in the DEAR-MI reported different
findings where the former observed higher post procedural
CK-MB in patients without thrombus aspiration and the latter
showed that the peak of CK-MB release was significantly
lower in patients with thrombus removal compared with the
control group (P value < 0.0001).
Our study found no significant difference between the two
studied groups regarding mortality at 30 days (P= 1.0).
This was also observed in the recently published TASTE
trial which was a multicenter, prospective, randomized, and
controlled, open-label clinical trial, with enrollment of patients
from the national comprehensive Swedish Coronary Angiogra-
phy and Angioplasty Registry (SCAAR). The primary end
point was all-cause mortality at 30 days. Frobert et al.28 con-
cluded no significant benefit of aspiration thrombectomy with
respect to mortality or any of several other clinical outcomes at
30 days. After follow-up for 1 year, the rate of death was 5.3%
in the thrombus-aspiration group, as compared with 5.6% in
the PCI-only group with no significant difference between
the two groups; P= 0.57.
The TOTAL trial conducted by Jolly et al. concluded that
routine manual thrombectomy did not reduce the risk of car-
diovascular death.25
The TROFI trial also concluded that thrombectomy does
not appear to reduce thrombus burden in patients with STEMI
undergoing primary PCI. In terms of clinical outcomes, there
were no differences between groups for cardiac death,
re-infarction in the territory of the infarction-related vessel,
all-cause death, stroke, definite stent thrombosis, or non-
target vessel revascularization.29
These conflicting results may reflect that the beneficial role
of thrombus removal may need a larger sample, multicenter
study with longer period of follow-up in order to be detected.5. Conclusion
Our study showed that routine thrombus aspiration during
primary PCI had no additional benefit regarding mortality, left
ventricular function, length of hospital stay, rehospitalization
due to cardiac cause and complications of PCI especially in
patients with low thrombus grade.Study limitations: the sample size is relatively small and lar-
ger studies are needed to validate these results. No long term
follow-up was done.
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